Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin + trabectedin for advanced malignant soft tissue tumors
jRCTs061240064Recruiting
- Start
- Dec 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of doxorubicin and trabectedin in soft tissue sarcoma (STS). Primary endpoint: Disease control rate. Started Dec 2024; status: recruiting.
02
Drugs
doxorubicintrabectedin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on jRCTs061240064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061240064.